{"id":451570,"date":"2021-03-05T02:25:22","date_gmt":"2021-03-05T07:25:22","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=451570"},"modified":"2021-03-05T02:25:22","modified_gmt":"2021-03-05T07:25:22","slug":"latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\/","title":{"rendered":"Latest lecanemab data to be presented at the AD\/PD\u2122 congress"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n STOCKHOLM<\/span>, March 5, 2021<\/span> \/PRNewswire\/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company and its collaboration partner Eisai will both present data relating to its investigational anti-amyloid beta (A\u03b2) protofibril antibody lecanemab (BAN2401), at the 15th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, AD\/PD\u2122 2021.<\/p>\n

The International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders – which due to the ongoing COVID-19 pandemic will be held online – is a key scientific event with a focus on improving the treatment of Alzheimer’s, Parkinson’s and other related neurodegenerative diseases.<\/p>\n

BioArctic’s poster presentation will focus on findings in a recent study of brain tissue samples and lecanemab which, together with the previously announced promising data from the large phase 2b<\/span> study of lecanemab in early Alzheimer’s disease, suggest that lecanemab could be of potential benefit for people with Down’s syndrome with signs of functional or cognitive deterioration.<\/p>\n

Eisai will present interim results from the ongoing open-label extension study of the Phase 2b<\/span> study of lecanemab in early Alzheimer’s disease. The presentation will focus on preliminary results concerning the effect of lecanemab on amyloid levels in the brain in subjects who participated in the core imaging subgroup.
\u00a0<\/p>\n

\n\n\n\n\n
\n

\n Topic, session, date and time (CET)<\/span>\n <\/p>\n<\/td>\n

\n

\n Topic<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Lecanemab (BAN2401)<\/span>\n <\/p>\n

\u00a0<\/p>\n

\n Session: A\u03b2 targeting therapies in AD 2
Saturday March 13
Oral presentation: 13:15-13:30
Live Q&A Session: 17:30-18:00<\/span>\n <\/p>\n<\/td>\n

\n

\n Preliminary amyloid PET analysis in BAN2401 phase 2 open-label extension in subjects who participated in the core imaging subgroup<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Lecanemab (BAN2401)<\/span>\n <\/p>\n

\n \u00a0<\/p>\n

\n Session: \u03b2-amyloid diseases\u00a0
March 9-14
Poster P142 \/ #487<\/span>\n <\/p>\n<\/td>\n

\n

\n Elevated levels of soluble amyloid beta protofibrils in Down’s syndrome and Alzheimer’s disease<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

—
This information was submitted for publication at 08:00 a.m. CET<\/span> on March 5, 2021<\/span>.<\/i>\u00a0\u00a0<\/p>\n

\n For further information, please contact:\u00a0<\/b>
\n
\n Gunilla Osswald<\/span>
\n
CEO, BioArctic AB\u00a0
E-mail: gunilla.osswald@bioarctic.se<\/a> \u00a0
Phone: +46 8 695 69 30\u00a0<\/p>\n

\n Oskar Bosson<\/span>
\n
Vice President Communications and Investor Relations
BioArctic AB\u00a0
E-mail: oskar.bosson@bioarctic.se<\/a> \u00a0
Phone: +46 70 410 71 80\u00a0<\/p>\n

This information was brought to you by Cision http:\/\/news.cision.com<\/a><\/p>\n

\n https:\/\/news.cision.com\/bioarctic\/r\/latest-lecanemab-data-to-be-presented-at-the-ad-pd–congress,c3300632<\/a>\n <\/p>\n

The following files are available for download:<\/p>\n

\n\n\n\n
\n

\n
\n https:\/\/mb.cision.com\/Main\/9978\/3300632\/1382659.pdf<\/a>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n Latest lecanemab data to be presented at the AD\/PD\u2122 congress<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n https:\/\/news.cision.com\/bioarctic\/i\/bioartic,c2885171<\/a>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n Bioartic<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

\u00a0<\/p>\n

\n \"Cision\" View original content:http:\/\/www.prnewswire.com\/news-releases\/latest-lecanemab-data-to-be-presented-at-the-adpd-congress-301241295.html<\/a><\/p>\n

SOURCE BioArctic<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire STOCKHOLM, March 5, 2021 \/PRNewswire\/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company and its collaboration partner Eisai will both present data relating to its investigational anti-amyloid beta (A\u03b2) protofibril antibody lecanemab (BAN2401), at the 15th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, AD\/PD\u2122 2021. The International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders – which due to the ongoing COVID-19 pandemic will be held online – is a key scientific event with a focus on improving the treatment of Alzheimer’s, Parkinson’s and other related neurodegenerative diseases. BioArctic’s poster presentation will focus on findings in a recent study of brain tissue samples and lecanemab which, together … <\/p>\n

Continue reading “Latest lecanemab data to be presented at the AD\/PD\u2122 congress”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-451570","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLatest lecanemab data to be presented at the AD\/PD\u2122 congress - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Latest lecanemab data to be presented at the AD\/PD\u2122 congress - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire STOCKHOLM, March 5, 2021 \/PRNewswire\/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company and its collaboration partner Eisai will both present data relating to its investigational anti-amyloid beta (A\u03b2) protofibril antibody lecanemab (BAN2401), at the 15th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, AD\/PD\u2122 2021. The International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders – which due to the ongoing COVID-19 pandemic will be held online – is a key scientific event with a focus on improving the treatment of Alzheimer’s, Parkinson’s and other related neurodegenerative diseases. BioArctic’s poster presentation will focus on findings in a recent study of brain tissue samples and lecanemab which, together … Continue reading "Latest lecanemab data to be presented at the AD\/PD\u2122 congress"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-05T07:25:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO00252&sd=2021-03-05\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Latest lecanemab data to be presented at the AD\\\/PD\u2122 congress\",\"datePublished\":\"2021-03-05T07:25:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\\\/\"},\"wordCount\":391,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO00252&sd=2021-03-05\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\\\/\",\"name\":\"Latest lecanemab data to be presented at the AD\\\/PD\u2122 congress - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO00252&sd=2021-03-05\",\"datePublished\":\"2021-03-05T07:25:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO00252&sd=2021-03-05\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO00252&sd=2021-03-05\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Latest lecanemab data to be presented at the AD\\\/PD\u2122 congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Latest lecanemab data to be presented at the AD\/PD\u2122 congress - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\/","og_locale":"en_US","og_type":"article","og_title":"Latest lecanemab data to be presented at the AD\/PD\u2122 congress - Market Newsdesk","og_description":"PR Newswire STOCKHOLM, March 5, 2021 \/PRNewswire\/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company and its collaboration partner Eisai will both present data relating to its investigational anti-amyloid beta (A\u03b2) protofibril antibody lecanemab (BAN2401), at the 15th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, AD\/PD\u2122 2021. The International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders – which due to the ongoing COVID-19 pandemic will be held online – is a key scientific event with a focus on improving the treatment of Alzheimer’s, Parkinson’s and other related neurodegenerative diseases. BioArctic’s poster presentation will focus on findings in a recent study of brain tissue samples and lecanemab which, together … Continue reading \"Latest lecanemab data to be presented at the AD\/PD\u2122 congress\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-05T07:25:22+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO00252&sd=2021-03-05","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Latest lecanemab data to be presented at the AD\/PD\u2122 congress","datePublished":"2021-03-05T07:25:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\/"},"wordCount":391,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO00252&sd=2021-03-05","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\/","name":"Latest lecanemab data to be presented at the AD\/PD\u2122 congress - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO00252&sd=2021-03-05","datePublished":"2021-03-05T07:25:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO00252&sd=2021-03-05","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO00252&sd=2021-03-05"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/latest-lecanemab-data-to-be-presented-at-the-ad-pd-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Latest lecanemab data to be presented at the AD\/PD\u2122 congress"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451570","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=451570"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451570\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=451570"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=451570"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=451570"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}